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Abstract
Background: Heat shock proteins (Hsps) are stress induced proteins with immunomodulatory properties. The Hsp70 of
Mycobacterium tuberculosis (TBHsp70) has been shown to have an anti-inflammatory role on rodent autoimmune arthritis
models, and the protective effects were demonstrated to be dependent on interleukin-10 (IL-10). We have previously
observed that TBHsp70 inhibited maturation of dendritic cells (DCs) and induced IL-10 production by these cells, as well as
in synovial fluid cells.
Methodology/Principal Findings: We investigated if TBHsp70 could inhibit allograft rejection in two murine allograft
systems, a transplanted allogeneic melanoma and a regular skin allograft. In both systems, treatment with TBHsp70
significantly inhibited rejection of the graft, and correlated with regulatory T cells (Tregs) recruitment. This effect was not
tumor mediated because injection of TBHsp70 in tumor-free mice induced an increase of Tregs in the draining lymph nodes
as well as inhibition of proliferation of lymph node T cells and an increase in IL-10 production. Finally, TBHsp70 inhibited
skin allograft acute rejection, and depletion of Tregs using a monoclonal antibody completely abolished this effect.
Conclusions/Significance: We present the first evidence for an immunosuppressive role for this protein in a graft rejection
system, using an innovative approach – immersion of the graft tissue in TBHsp70 solution instead of protein injection. Also,
this is the first study that demonstrates dependence on Treg cells for the immunosuppressive role of TBHsp70. This finding
is relevant for the elucidation of the immunomodulatory mechanism of TBHsp70. We propose that this protein can be used
not only for chronic inflammatory diseases, but is also useful for organ transplantation management.
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Introduction
Heat shock proteins (Hsp) are highly immunogenic proteins,
though conserved between mammals and microorganisms. Hsp70,
originally described as a heat induced protein [1], is the most
conserved of Hsps, and currently known to have immunomodu-
latory properties. Nevertheless, the exact mechanisms through
which it exerts this effect are not completely clear [2].
Mycobacterium tuberculosis Hsp70 (TBHsp70) has been shown to
protect from induced arthritis in rats [3,4,5]. We have demon-
strated that TBHsp70 induces IL-10 production by monocytes and
synovial cells of arthritis patients, leading to a reduction of TNF-a
e IFN-c levels [6]. Also, we observed that TBHsp70 can inhibit
differentiation of bone marrow derived dendritic cells (BMDCs) in
vitro, leading to the production of IL-10 by these cells [7]. It was
suggested that exposure to bacterial Hsps could activate self Hsp-
specific T cells that would be cross reactive with bacterial Hsps
and trigger immunoregulatory pathways [8]. More recently, in a
proteoglycan-induced arthritis model, TBHsp70 immunization
showed a protective potential that was dependent on IL-10 [9]. In
addition, the treatment with TBHsp70 upregulated IL-10 mRNA
in regulatory T cells (Tregs).
Treg cells are crucial for the suppression of acute rejection in
allografts [10]. These cells develop in the thymus or can be
induced in peripheral sites when given appropriate signals by the
antigen presenting cells. They are CD25+, and also express the
transcriptional factor forkhead box 3 (FoxP3), cytotoxic T-
lymphocyte antigen 4 (CTLA-4) and glucocorticoid-induced
tumor necrosis factor receptor (GITR) [11]. They can suppress
inflammatory responses by regulating the activity of self-reactive
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actively suppress non-Treg proliferation [12]. They have been
shown to be important for inhibition of allograft rejection in
several models [13,14]. In this study, we investigated whether
TBHsp70 could act as an immunosuppressant in two allograft
rejection systems. We also investigated if treatment with this
protein would induce Treg cells. Our results suggest that
TBHsp70 is capable of delaying acute allograft rejection, and this
response is mediated by Tregs.
Results
TBHsp70 suppresses tumor allograft rejection
We asked if TBHsp70 could inhibit allograft rejection in two
different models. We first used a transplanted allogeneic tumor
model, injecting BALB/c mice (H-2
d) with B16F10 melanoma
cells (H-2
b). Cells were resuspended in PBS containing TBHsp70
or no stimulus and were injected subcutaneously in mice. Tumor
growth was recorded daily for 12 days. Around day 6 after
injection, PBS-injected mice completely rejected the tumor cells,
and the progressive elimination of the dark area occupied by
melanoma cells could be observed at the injection site (Fig. 1A).
However, mice that received tumor cells with TBHsp70 not only
did not reject the tumor (Fig. 1A), but also allowed tumor growth
through the 12-day period (Fig. 1B). These results suggested that
TBHsp70 could inhibit tumor allograft rejection, supporting the
immunosuppressive potential that had been previously observed in
arthritis models [3,4,15,16].
T cells with regulatory phenotype are observed at the
tumor allograft site in HSP70-treated animals
We next investigated whether the inhibition of rejection of
allogeneic tumor cells by TBHsp70 was associated with a local
infiltration by Treg cells. We performed immunohistology on the
tumor graft site, and sections were incubated with anti-CD4, anti-
CD25, anti-FoxP3, and anti-GITR antibodies (Fig. 2). In mice
injected with tumor cells in PBS alone, the tumor cells were not
detectable by histology at the injection site, as analyzed by
hematoxillin/eosin staining. Also, immunohistochemistry for
CD4, CD25, FoxP3 and GITR was negative (Fig. 2A). In mice
injected with tumor cells in TBHsp70 solution, staining for CD4,
CD25, FoxP3 and GITR was observed in overlapping areas,
mostly surrounding the tumor mass, as well as inside the tumor
(Fig. 2A). This indicates that Tregs were locally infiltrating the
tumor allograft site. Figure 2B shows the quantification of CD4,
CD25, FoxP3 and GITR staining, captured with the Image Pro-
Plus and quantified using the color range function in Adobe
Photoshop tool.
Injection of TBHsp70 suppresses T cell proliferation and
induces Treg cells
Tumors can develop varied immunosuppressive strategies in
order to grow [17], and those include the recruitment of Tregs
[18,19,20]. It was possible that the Tregs observed infiltrating the
TBHsp70 treated tumors could be a result of tumor activity, rather
than a direct effect of TBHsp70. To investigate this possibility,
tumor-free mice were injected subcutaneously with TBHsp70
(30 mg) or PBS, and after 4 days they were sacrificed. Draining
lymph nodes were excised and a single cell suspension was
obtained. Cells were counted and stained for the presence of Treg
cells, with anti-CD4 Cychrome, anti-Foxp3 PE and anti-CD25
FITC, and analyzed by flow citometry. The injection of TBHsp70
led to a 2.4-fold increase in the percentage of CD25+ Foxp3+ cells
among CD4+ lymphocytes compared to the PBS-injected animals
(Fig. 3A). Because the total number of cells was also increased two-
fold in the lymph nodes of tumor-treated animals, the total
increase in CD4+ CD25+ Foxp3+ was approximately four-fold,
compared to the PBS-injected animals (Fig. 3A). This result
supported our hypothesis that TBHsp70 could induce Treg cells in
the draining lymph node.
The lymph nodes are the sites to which antigens from the
periphery are drained by the lymphatic system [21], and
subcutaneous injection of antigens results on the presentation of
such antigens to T cells in the draining lymph nodes [22]. Cell
interactions occurring in the draining lymph nodes are thus crucial
to the immune responses leading to allograft rejection or
acceptance [23]. To determine whether the immunosuppressive
effects of TBHsp70 would affect T cell proliferation in the draining
lymph node, we injected mice subcutaneously with PBS, TBHsp70
or Dexamethasone (DEXA) as a positive control for suppression of
proliferation. Four days later, the draining inguinal lymph nodes
were excised, a single cell suspension was obtained and the cells
were cultured with PHA for another four days. Viability of
proliferating cells was estimated by an MTT assay. As expected,
mice injected with DEXA exhibited significant inhibition of
polyclonal T cell proliferation (Fig. 3B). Surprisingly, TBHsp70
inhibition of lymph node cell proliferation was superior to the
inhibition induced by DEXA (Fig. 3B). Supernatants from cell
cultures were analyzed for the presence of IL-10, TNF-a, IL-4, IL-
6, IFN-c, IL-17A and TGF-b. IL-10 production was significantly
upregulated by treatment with TBHsp70 as well as by the
treatment with DEXA, and both treatments significantly inhibited
Figure 1. B16F10 tumor allograft in BALB/c mice. (A) Typical
aspect of injection site in mice treated subcutaneously with tumor cells
in PBS containing TBHsp70 or PBS alone on day 12 after transplant of
tumor cells. (B) Sequential measurements of tumor diameter. n=3 mice
per treatment group. This experiment was performed seven times, with
identical results. ***, p,0.0001.
doi:10.1371/journal.pone.0014264.g001
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other cytokines analyzed, including TGF-b. These results
indicated that TBHsp70 treatment leads to suppression of lymph
node T cell proliferation in vitro, and this is associated with the
upregulation of IL-10 production and inhibition of TNF-a.
Altogether, the results suggested that TBHsp70 could induce
Tregs which correlated with the induction of IL-10 in the draining
lymph node, and that was independent of the presence of tumor
cells.
TBHsp70 treatment delays skin allograft rejection
To further characterize the immunosuppressive effect of
TBHsp70 over allograft rejection, and to eliminate the tumor cell
variable, we switched to a traditional skin allograft model. We
transferred a section of tail skin from C57BL/6 mice to BALB/c
mice. The donor skin was immersed in a PBS solution containing
TBHsp70 (30 mg in 500 ml, or 60 mg/ml) or PBS alone for 60
minutes at 4uC, and the graft site was analyzed daily. These
experimental conditions were chosen because we had previously
tested the injection of TBHsp70 at the graft site, either before or
after performing the graft, and immersion of the donor graft in the
TBHsp70 solution showed the best effect for a single TBHsp70
treatment (data not shown). We also tested immersing the graft in
20, 40 and 60 mg/ml of TBHsp70 solution, and the latter
concentration presented the best results. At day 9, mice that
received the skin grafts treated with PBS alone completely rejected
the graft (Fig. 4A, B). On the other hand, mice receiving
TBHsp70-treated skin graft presented prolonged acceptance of
graft until day 17 (Fig. 4B). These results suggested that treatment
with TBHsp70 significantly delays skin allograft rejection
(p=0.0455). To confirm the specificity of the regulatory effects
observed with TBHsp70 treatment, we repeated the graft
experiments using different proteins. Hsp90 was used to
demonstrate that the effect is not a general property of Hsps,
but rather of TBHsp70. Ovalbumin is a largely used antigen
control, and was also used by us to treat the skin before grafting.
Finally, we treated skin fragments with TBHsp70 boiled for
10 min at 100uC, to exclude the possibility that the effect could be
due to a heat-resistant contaminant (such as LPS has been
described to be [24,25]). Once again, only TBHsp70 treatment
was capable to prolong the allograft acceptance (Fig. 4C,
p=0.0246).
Treg cells are essential for skin allograft survival induced
by TBHsp70
We next asked whether TBHsp70-prolonged survival of skin
allograft was mediated by Tregs. To investigate this possibility, we
depleted these cells by treating recipient BALB/c mice with anti-
CD25 mAb (PC61). Depletion with one injection of this antibody
is known to eliminate ,70% of Tregs [26]. We performed a single
mAb injection two days post-transplant (Fig. 5A). This treatment
resulted in ,95% depletion of CD4+CD25+ T cells (Fig. 5B).
Depletion of CD25+ T cells in TBHsp70 treated mice
completely abolished the suppressive effect (Figure 5C). Once
again, TBHsp70-treated skin allografts had a significant prolonged
survival compared to OVA-treated grafts (p=0.0295). Interest-
ingly, depletion of Treg cells diminished this effect. Mice that were
treated with PC61 mAb and TBHsp70 showed decreased graft
survival compared to the TBHsp70-treated, not depleted mice
(p=0.0246). Taken together, these results indicate that the
Figure 2. Treg cells are observed at the tumor allograft site. (A) Graft site (8 mm) serial sections from mice injected with tumor in PBS or
TBHsp70 were stained with biotin-labeled anti-CD4, anti-CD25, anti-GITR and anti-Foxp3 antibodies, followed by streptavidin-peroxidase. Counter
staining was hematoxillin. (B) Quantification of positive staining, expressed in pixels, using Image Pro Plus Software. n=3 mice per group,
experiments were performed 3 times.
doi:10.1371/journal.pone.0014264.g002
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Treg cells.
Discussion
In this study, we investigated the ability of TBHsp70 to inhibit
allograft rejection in two different models as well as the mechanism
mediating this effect. Although TBHsp70 exerts suppressive effects
in inflammatory diseases, the mechanism by which it does so has
not been fully elucidated. However, the induction of IL-10
production and the suppression of inflammatory cytokines seem to
be consistent findings associated with TBHsp70 immunomodula-
tory effects [5,9,15].
The immunoregulatory role performed by Tregs is also
frequently associated with the production of IL-10 [27,28]. We
demonstrated here, for the first time, that the immunosuppressive
effect of TBHsp70 depends on Tregs. This was correlated with
production of IL-10 in the draining lymph nodes. We have
demonstrated in previous studies that TBHsp70 can induce IL-10
production by monocytes [6] and immature DCs [7]. Thus, it is
possible that the IL-10 detected in our experiments is not solely
produced by Tregs. This needs to be ascertained in further
experiments with intracellular staining. Because Tregs can be
induced locally by DCs with an immature phenotype that produce
IL-10 [13,29,30], it is possible that TBHsp70 modulates the
phenotype of DCs, inducing a regulatory response, and IL-10
production by DCs, leading to the recruitment and/or induction
of Tregs. The importance of donor DC modulation for graft
acceptance and Treg generation has been demonstrated in
different systems [30,31,32].
Importantly, we verified that the induction of IL-10 in lymph
nodes of TBHsp70 injected mice correlated with inhibition of
TNF-a. This result corroborates an observation made by us in a
previous study, in which in vitro treatment of synovial cells from
arthritis patients with TBHsp70 inhibited TNF-a and induced IL-
10 production [6]. This ability is likely to be determinant for the
immunosuppressive effects verified for this protein both in arthritis
and in the graft system. Interestingly, TGF-b, another cytokine
commonly linked to Treg activity (or specific subsets of Tregs – see
review in [33]) does not seem to be involved in this process, at least
not in our experimental system.
We cannot conclude from the evidence presented here that the
Tregs observed are specific for TBHsp70. It has, however, been
hypothesized, that Hsp70 peptides constitute ligands for Treg cells
[8]. This hypothesis is not completely excludent from the first one.
Nevertheless, we believe that additional studies are necessary to
discern from these two hypotheses, both in arthritis and transplant
systems, to verify if the effect can be reproduced exclusively with
Figure 3. Local injection of TBHsp70 induces Tregs, IL-10 and leads to suppression in the draining lymph nodes. (A) Mice were
injected subcutaneously in the thigh with PBS or 30 mg of TBHsp70. Draining lymph nodes were excised 4 days later, and cells were stained with
fluorescent antibodies for CD4 and CD25, or CD4 and Foxp3. Plots show events gated on CD4+ cells. (B) Mice were injected subcutaneously in the
thigh with TBHsp70 (1.5 mg/kg), DEXA (0.25 mg/kg) or PBS. Draining lymph nodes were excised 4 days later and single cell suspensions of lymph
nodes were stimulated in vitro for 4 days with 0, 0.5, 1, or 2% of PHA. Viability of cells proliferating in response to PHA was estimated by an MTT assay,
O.D. being read at 570 nm. Data are expressed as percentage of PHA-inhibited proliferation considering the O.D. at each PHA concentration as 100%
proliferation. (C) Cytokine production of cultures supernatants was analyzed by flow cytometry, using a CBA (Mouse Th1/Th2/Th17) kit, except for
TGF-b production, which was analyzed by ELISA. *, p,0.05; **, p,0.01.
doi:10.1371/journal.pone.0014264.g003
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occur in rats as well as in mice, with different MHC elements, it
could be predicted that multiple peptides of this protein would be
candidate ligands. However, it is also possible that such peptide
ligands do exist, and yet it is still necessary to initiate the response
with DC modulation by TBHsp70 in its native structure. Indeed,
the abrogation of suppressive effect of TBHsp70 by boiling
suggests this might be a possibility. If so, the immunomodulatory
Figure 4. TBHsp70 delays skin graft rejection. (A) Skin grafts were immersed in a PBS solution (500 ml) containing TBHsp70 (30 mg) or PBS alone
for 60 minutes at 4uC. After this, the skin graft was sutured to the exposed tissue of the recipient. Animals were kept in individual mini-isolators and
observed daily, the state of graft acceptance being photographed and recorded. Graft rejection was confirmed by the observation of cyanosis,
erythema, erosion, and loss of skin graft. (B) Survival curve of skin allograft immersed in PBS alone or TBHsp70 (30 mg). (C) Skin grafts were immersed
in a PBS solution (500 ml) containing Ovalbumin (30 mg), Hsp90 (30 mg), 30 mg of TBHsp70 boiled for 10 minutes at 100uC or native TBHsp70. *,
p,0.05. n=3 mice per treatment group, the experiments were performed 4 times.
doi:10.1371/journal.pone.0014264.g004
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DCs treated with TBHsp70, and antigen processing inhibition in
this system could indicate the relevance of TBHsp70 peptide
presentation for the induction of Tregs. We are currently
performing such experiments.
An attractive and innovative feature of TBHsp70 treatment in
our system was that it was local, rather than systemic. All
immunosuppressive drugs are delivered systemically, leading to
undesirable side effects [34,35,36]. We verified that local treatment
with TBHsp70 had a local effect, though it still remains to be
determined if any systemic alterations were induced. Also, we were
able to observe a significant difference with only one dose of the
protein, while most immunosuppressants are used daily. Further
studies need to be performed to determine how long additional
doses of the protein will extend survival and acceptance of the graft.
Finally, we observed that the best effect on prolonged skin allograft
survival was obtained immersing the graft in a TBHsp70 solution.
The solutions used for preservation of organs before transplant are
mainly buffered saline solutions that aim to protect from ischemia/
reperfusion damage [37,38,39]. Although the endogenous Hsp70
protects organs against ischemia [40,41], we do not believe that this
was the mechanism of action involved in the inhibition of rejection in
our study, because it was abolished by depletion of Tregs.
Nonetheless, our results suggest that this protein could be used in
the preservation solution of solid organs, conferring an additional
benefit in the use of these preparations, delaying acute rejection.
Materials and Methods
Mice
Female BALB/c and C57BL/6 mice between 6–8 weeks old
were purchased from FEPPS (Rio Grande do Sul, Brazil). All
animals were housed in individual and standard mini-isolators
(Techniplast, Italy) in an SPF facility (Faculdade de Biociencias –
PUCRS) and had free access to water and food. All procedures
were previously reviewed and approved by the Ethics Committee
for the Use of Animals of Pontifı ´cia Universidade Cato ´lica do Rio
Grande do Sul (CEUA-PUCRS) under protocol ID CEUA 08/
00048.
Protein purification and LPS extraction
RecombinantTBHsp70 was producedinXL1-blue Escherichia coli
(E.coli) (a gift from Dr Douglas Young, Hammersmith Hospital,
London, UK), and purified according to Mehlert [42]. Estimation
of protein concentrationand itspuritywasperformed against a BSA
standard curve on a 10% SDS-PAGE gel stained with Coomassie
blue. To remove LPS, Triton X-114 was used according to the
method described in Aida [43]. Briefly, 5 ml of Triton X-114
(Sigma) were added to 500 ml recombinant protein. After vortexing
vigorously, the solution was incubated in ice for 5 min, vortexed
again and incubated at 37uC for 5 min. The solution was then
centrifuged for 5 minutes at 37uC and the supernatant collected and
the procedure repeated 5 more times. Contaminating Triton was
removed by incubating overnight with Biobeads (Bio-Rad) at 4uC
with agitation. To test for remaining contaminant LPS, a bioassay
was performed. BALB/c mice were injected i.v. with 100 ml volume
of either PBS alone, PBS with 40 mg of LPS (Sigma) or PBS with
40 mg TBHsp70. Mice were sacrificed 6 hours after injection. The
spleens were removed, collagenase D treated, and the single cell
suspensions obtained were analyzed for CD11c and CD86
expression by flow cytometry, as described in Khoruts et al. [44].
Preparations were considered LPS free only when CD86 was not
upregulated in splenic DCs.
Figure 5. CD4+CD25+ regulatory T cells are crucial for prolonged survival induced by TBHsp70. Mice were injected i.p. with a single
injection of 150 mg anti-CD25 mAb (PC61). (A) Schematic representation of in vivo Treg depletion and transplantation. (B) For depletion confirmation,
lymph nodes were excised, collagenase D treated, stained with anti-CD4 and anti-CD25 and analyzed by flow cytometry. (C) Survival curve of skin
allograft immersed in PBS containing 30 mg of OVA or TBHsp70. Groups were CD25+ depleted or not depleted. *, p,0.05. n=3 mice per treatment
group. Depletions were performed 2 times.
doi:10.1371/journal.pone.0014264.g005
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T cell proliferative responses were determined by a modified
colorimetric assay [45]. To analyze inhibition of murine cell
proliferation in vitro, mice were injected subcutaneously in the
thigh with TBHsp70 (1.5 mg/kg), DEXA (0.25 mg/kg) or PBS.
Draining lymph nodes were excised 4 days later and single cell
suspensions of lymph nodes (8610
5/ml) were cultured with 0, 0.5,
1, or 2% of PHA for 4 days.
For the MTT assay, in the last 4 h of culture, 100 ml of the
supernatant was gently discarded and 30 ml of freshly prepared
MTT (3-(4,5-diamethyl 2-thiazolyl) 2,5 diphenyl-2H-tetrazolium -
Sigma) solution (5 mg/ml in RPMI 1640 - Sigma) was added to
each well. The cell cultures were incubated for 4 h at 37uCi n5 %
CO2 atmosphere. After completely removal of the supernatant,
100 ml of DMSO (Sigma) was added to each well. The optical
density (OD) was determined using a Biorad ELISA plate reader
at a wavelength of 570 and 620 nm. The viability of proliferating
cells was expressed as the percentage of inhibited PHA-induced
proliferation.
Cytokine measurement
To analyze the profile of cytokine production, mice were
injected subcutaneously in the thigh with TBHsp70 (1.5 mg/kg),
DEXA (0.25 mg/kg) or PBS. Draining lymph nodes were excised
4 days later and single cell suspensions of lymph nodes (8610
5/ml)
were cultured with 5 mg of conA for 4 days.
Murine cell culture supernatants were analyzed by a CBA
mouse Th1/Th2/Th17 kit by flow cytometry using a FACSCa-
libur (Beckton Dickinson) according to manufacturer’s instruc-
tions. TGF-b measurements were made using a Human/Mouse
TGF-B1 ELISA Ready-Set-Go! Kit (eBioscience).
Tumor injections and measurements
B16F10 cells were cultured in complete DMEM (Sigma) with
10% fetal calf serum (FCS). BALB/c mice were anesthetized
(intraperitoneally) with a 100 ml volume of PBS 34% ketamine,
10% xylazine and fur from the upper thigh was removed.
Cultured tumor cells that were 80% confluent were detached from
the tissue culture plate with PBS 15 mM EDTA, washed, counted
and ressuspended to a density of 1.5610
6 cells in 150 ml PBS
containing either LPS-free TBHsp70 (30 mg) or PBS alone. These
mixtures were injected subcutaneously in the outer region of the
thigh of mice. Tumor diameter was measured with a caliper and
photographed daily, for a period of two weeks. These experiments
were repeated six times.
Immunohistology
Lymph nodes and thighs of the tumor-injected animals were
embedded in tissue-freezing medium (Tissue-Tek - Miles Labora-
tories), and stored in liquid nitrogen. Serial cryostat sections were
mounted on poly-L-lysine-covered glass slides and fixed for 10 min
in cold acetone, washed in PBS, and incubated for 30 min in a wet
chamber at room temperature with PBS and normal goat serum
(Sigma-Aldrich) diluted 1/50 to reduce nonspecific binding and
then incubated for 40 min with biotinylated anti-CD4, anti-CD25,
anti-GITR or anti-FoxP3, according to a previous titration assay.
Next, sections were incubated with avidin-biotin-peroxidase
complex, the color developed with 3,39-diaminobenzidine (Vector
Laboratories). The slides were counterstained with Mayer
hematoxylin, dehydrated, and mounted with Canada Balsam.
The software used to capture and count the cells was the Image
Pro-plus version 4.1.5 (Mediacybernetics), which uses a video
camera connected to a computer card to capture the images of the
selected microscopic field. Structures were selected on the
computer screen with the mouse pointer and then counted
manually. Histological sections were captured by ZEISS –
Axioskope 40 microscope equipped with a CoolSNAP-PRO color
camera. Positive cells to CD4, CD25, GITR and FoxP3 were
counted at 400x magnification, and photographs had the number
of pixels quantified in each section, using the Image Pro Plus
Software (version 4.1.5, Media Cybernetics Inc., Bethesda) and the
color range Adobe Photoshop tool. Histology was performed 3
times, in different experiments.
Skin Graft Model
For the experimental model of skin graft, the proceeding
described by Billingham and Medawar was employed [46]. Briefly,
C57BL/6 donor mice were sacrificed, 1 cm
2 sections of tail skin
were removed and immersed in a PBS solution (500 ml) containing
TBHsp70 (30 mg), or PBS alone for 60 minutes at 4uC. Control
treatments were PBS solutions (500 ml) containing either 30 mgo f
Hsp90 (StressGen), 30 mg of Ovalbumin (Sigma) or 30 mgo f
TBHsp70 boiled for 10 minutes at 100uC. BALB/c recipient mice
were anesthetized as described above, and fur was shaved off the
dorsal trunk. At the shaved area, 1 cm
2 of skin was removed in
each recipient mouse. One donor tail skin fragment was sutured to
the exposed tissue of each recipient. Animals were kept in
individual cages and observed daily, the state of graft acceptance
being photographed and recorded. Graft rejection was confirmed
by the observation of cyanosis, erythema, erosion, and loss of skin
graft. Each experiment was performed four times.
In vivo Tregs depletion
Mice were injected i.p. a single injection containing 150 mgo f
anti-CD25 mAb, purified from PC61 hybridoma culture super-
natant using a protein A column (Sigma), or with PBS. The
injection was given 2 days after skin transplantation. PC61
hybridoma cells were kindly provided by Dr. Ross Kedl, National
Jewish, Denver, Colorado. Efficiency of depletion was analyzed by
flow cytometry of lymphoid organs, staining for CD4, CD25 and
FoxP3.
Flow cytometry
Lymph nodes from mice injected with different treatments were
excised after animals were sacrificed, and the organs disrupted
against a nylon screen in media containing Collagenase D (Roche).
Single cell suspensions were obtained, cells counted with Trypan
blue and stained with antibodies against CD4-cychrome, CD25-
PE and Foxp3-biotin, followed by streptavidin-FITC; or CD11c-
FITC and CD86-PE (all purchased from Pharmingen). Cells were
analyzed in a FACSCalibur flow cytometer (Bekton Dickinson).
Statistical analysis
Statistical analysis was performed using the Prism software
(version 5.00, Graphpad Software Inc., San Diego). The one-way
ANOVA test was used to determine differences between groups.
Multiple comparisons among levels were checked with Bonferroni
post hoc tests. Differences between specific points were determined
by a t test. To analyze skin graft survival, the Kaplan-Meier
method was used. The level of significance was set at p,0.05.
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